The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation
Open accessAbstract
A multicenter analysis was conducted to evaluate the main prognostic factors driving survival after radioembolization using yttrium-90–labeled resin microspheres in patients with hepatocellular carcinoma at eight European centers. In total, 325 patients received a median activity of 1.6 GBq between September 2003 and December 2009, predominantly as whole-liver (45.2%) or right-lobe (38.5%) infusions. Typically, patients were Child-Pugh class A (82.5%), had underlying cirrhosis (78.5%), and had good Eastern Cooperative Oncology Group (ECOG) performance status (ECOG 0-1; 87.7%), but many had multinodular disease (75.9%) invading both lobes (53.1%) and/or portal vein occlusion (13.5% branch; 9.8% main). Over half had advanced Barcelona Clinic Liver Cancer (BCLC) staging (BCLC C, 56.3%) and one-quarter had intermediate staging (BCLC B, 26.8%). The median overall survival was 12.8 months (95% confidence interval, 10.9-15.7), which varied significantly by disease stage (BCLC A, 24.4 months [95% CI, 18.6-38.1 months]; BCLC B, 16.9 months [95% CI, 12.8-22.8 months]; BCLC C, 10.0 months [95% CI, 7.7-10.9 months]). Consistent with this finding, survival varied significantly by ECOG status, hepatic function (Child-Pugh class, ascites, and baseline total bilirubin), tumor burden (number of nodules, alpha-fetoprotein), and presence of extrahepatic disease. When considered within the framework of BCLC staging, variables reflecting tumor burden and liver function provided additional prognostic information. The most significant independent prognostic factors for survival upon multivariate analysis were ECOG status, tumor burden (nodules >5), international normalized ratio >1.2, and extrahepatic disease. Common adverse events were: fatigue, nausea/vomiting, and abdominal pain. Grade 3 or higher increases in bilirubin were reported in 5.8% of patients. All-cause mortality was 0.6% and 6.8% at 30 and 90 days, respectively. Conclusion: This analysis provides robust evidence of the survival achieved with radioembolization, including those with advanced disease and few treatment options. (HEPATOLOGY 2011;)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
Forner, A., Reig, M. E., Rodriguez de Lope, C., & Bruix, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247133 · Cited by 1,110
Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., Atassi, B., Baker, T., Gates, V., Miller, F. H., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.006 · Cited by 1,074
Kennedy, A., Nag, S., Salem, R., Murthy, R., McEwan, A. J., Nutting, C., Benson, A., Espat, J., Bilbao, J. I., Sharma, R. A., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.11.060 · Cited by 676
Self-citationSalem, R., Lewandowski, R. J., Kulik, L., Wang, E., Riaz, A., Ryu, R. K., Sato, K. T., Gupta, R., Nikolaidis, P., Miller, F. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.049 · Cited by 650
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort†
Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Hepatology · doi:10.1002/hep.20636 · Cited by 637
Kulik, L. M., Carr, B. I., Mulcahy, M. F., Lewandowski, R. J., Atassi, B., Ryu, R. K., Sato, K. T., Benson, A., Nemcek, A. A., Gates, V. L., et al. (2008) · Hepatology · doi:10.1002/hep.21980 · Cited by 620
Hill, T., & Lewicki, P. (2006) · Medical Entomology and Zoology · Cited by 583
Prospective validation of the Barcelona Clinic Liver Cancer staging system
Cillo, U., Vitale, A., Grigoletto, F., Farinati, F., Brolese, A., Zanus, G., Neri, D., Boccagni, P., Srsen, N., D'Amico, F., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.015 · Cited by 425
Risk Factors for the Rising Rates of Primary Liver Cancer in the United States
El-Serag, H. B., & Mason, A. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3227 · Cited by 418
Kennedy, A. S., Nutting, C., Coldwell, D., Gaiser, J., & Drachenberg, C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.09.004 · Cited by 407
Liver disease induced by radioembolization of liver tumors: Description and possible risk factors
Sangro, B., Gil‐Alzugaray, B., Rodriguez, J., Sola, I., Martinez‐Cuesta, A., Viudez, A., Chopitea, A., Iñarrairaegui, M., Arbizu, J., & Bilbao, J. I. (2008) · Cancer · doi:10.1002/cncr.23339 · Cited by 369
Self-citationYttrium-90 microspheres for the treatment of hepatocellular carcinoma
Geschwind, J. F. H., Salem, R., Carr, B. I., Soulen, M. C., Thurston, K. G., Goin, K. A., van Buskirk, M., Roberts, C. A., & Goin, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.034 · Cited by 355
Self-citationKulik, L. M., Atassi, B., van Holsbeeck, L., Souman, T., Lewandowski, R. J., Mulcahy, M. F., Hunter, R. D., Nemcek, A. A., Abecassis, M. M., Haines, K. G., et al. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20609 · Cited by 333
Carr, B. I. (2004) · Liver Transplantation · doi:10.1002/lt.20036 · Cited by 261
Kennedy, A. S., McNeillie, P., Dezarn, W. A., Nutting, C., Sangro, B., Wertman, D., Garafalo, M., Liu, D., Coldwell, D., Savin, M., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.005 · Cited by 243
Self-citationGrieco, A., Pompili, M., Caminiti, G., Miele, L., Covino, M., Alfei, B., Rapaccini, G. L., & Gasbarrini, G. (2005) · Gut · doi:10.1136/gut.2004.048124 · Cited by 242
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Jelic, S., & Sotiropoulos, G. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq166 · Cited by 228
Goin, J. E., Salem, R., Carr, B. I., Dancey, J. E., Soulen, M. C., Geschwind, J. F. H., Goin, K., Van Buskirk, M., & Thurston, K. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.00001142592.89564.f9 · Cited by 170
Self-citationTransarterial therapies for hepatocellular carcinoma
Sangro, B., D’Avola, D., Iñarrairaegui, M., & Prìeto, J. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.545346 · Cited by 38
Self-citation
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Self-citationA global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Metadata
- Authors
- Sangro, B., Carpanese, L., Cianni, R., Golfieri, R., Gasparini, D., Ezziddin, S., Paprottka, P. M., Fiore, F., Van Buskirk, M., Bilbao, J. I., Ettorre, G. M., Salvatori, R., Giampalma, E., Geatti, O., Wilhelm, K., Hoffmann, R. T., Izzo, F., Iñarrairaegui, M., Maini, C. L., Urigo, C., Cappelli, A., Vit, A., Ahmadzadehfar, H., Jakobs, T. F., & Lastoria, S.
- Venue
- Hepatology
- Published
- 2011-09-02
- Volume
- 54
- Issue
- 3
- Pages
- 868-878
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2066593706
- Cited by
- 652
- References
- 24
- FWCI
- 27.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.